OTCMKTS:TLPPF Telix Pharmaceuticals (TLPPF) Stock Price, News & Analysis $12.63 +0.28 (+2.27%) (As of 07/3/2024 ET) Add Compare Share Share Today's Range$12.29▼$12.7050-Day Range$9.50▼$13.0052-Week Range$5.30▼$13.50Volume9,603 shsAverage Volume7,956 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Telix Pharmaceuticals alerts: Email Address Ad Behind the MarketsMajor Pharma Deals Propel This Undervalued AI StockYou need to check out this game-changing biotech stock. Their physics-based software can model how molecules behave and identify ideal drug candidates in record time. Big Pharma is taking notice.Reveal the AI Company Disrupting Drug Discovery Here >>> About Telix Pharmaceuticals Stock (OTCMKTS:TLPPF)Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its products portfolio include Illuccix for the treatment of prostate cancer;, TLX591, a radio antibody-drug conjugate, which is in phase 3 clinical trial for the treatment of prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.Read More TLPPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLPPF Stock News HeadlinesMay 19, 2024 | investing.comTelix Pharmaceuticals plans Nasdaq listingMay 17, 2024 | finance.yahoo.comTelix Files Registration Statement for Proposed Initial Public Offering in the United StatesJuly 3, 2024 | Behind the Markets (Ad)AI depends on this... Your retirement could too!Imagine owning a piece of the backbone powering the AI revolution. Wall Street says it's extremely undervalued - a downright steal compared to peers. We call it the "Last Retirement Stock You'll Ever Need."May 17, 2024 | globenewswire.comTelix Files Registration Statement for Proposed Initial Public Offering in the United StatesApril 29, 2024 | seekingalpha.comCLRPF Clarity Pharmaceuticals LtdApril 18, 2024 | markets.businessinsider.comUBS Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)April 16, 2024 | finance.yahoo.comTelix Pharmaceuticals Limited (TLPPF)April 11, 2024 | finance.yahoo.comTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.July 3, 2024 | Behind the Markets (Ad)AI depends on this... Your retirement could too!Imagine owning a piece of the backbone powering the AI revolution. Wall Street says it's extremely undervalued - a downright steal compared to peers. We call it the "Last Retirement Stock You'll Ever Need."April 11, 2024 | businesswire.comTelix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.March 21, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Telix Pharmaceuticals Ltd. (TLPPF)March 18, 2024 | finance.yahoo.comQDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical TherapyMarch 11, 2024 | finance.yahoo.comAppointment of Dr Darren Patti to Group Chief Operating OfficerMarch 5, 2024 | markets.businessinsider.comAustralian Stocks: Telix (TLX) Bolsters Supply Chain with AU$126M ARTMS DealFebruary 23, 2024 | markets.businessinsider.comStrong Buy Rating for Telix Pharmaceuticals Amidst Revenue Surge and Market Expansion OpportunitiesFebruary 22, 2024 | msn.comTelix Pharmaceuticals GAAP EPS of A$1.61, revenue of A$502.55MFebruary 7, 2024 | msn.comQSAM to be acquired by Telix for $33.1M plus $90M CVRJanuary 2, 2024 | morningstar.comTelix Pharmaceuticals Ltd Ordinary SharesDecember 26, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)December 25, 2023 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)December 11, 2023 | finance.yahoo.comFirst Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging AgentDecember 6, 2023 | finance.yahoo.comPositive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCSNovember 8, 2023 | finance.yahoo.comTelix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic RegionOctober 19, 2023 | msn.comTelix Pharmaceuticals reports Q3 resultsOctober 18, 2023 | finance.yahoo.comProstACT SELECT Study of TLX591 Interim Readout: Positive Results Confirm Safety and TolerabilitySeptember 6, 2023 | finance.yahoo.comTelix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANMAugust 24, 2023 | markets.businessinsider.comWilsons Keeps Their Buy Rating on Telix Pharmaceuticals Ltd. (TLPPF)See More Headlines Receive TLPPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:TLPPF CUSIPN/A CIKN/A Webtelixpharma.com Phone61-3-3093-3897FaxN/AEmployees234Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Darren Smith B.Bus. (Age 59)FCPA, M.B.A., Group Chief Financial Officer Comp: $380.97kDr. Andreas Kluge M.D. (Age 59)Ph.D., Chief Medical Advisor & Non-Executive Director Comp: $28.68kMr. Richard Valeix M.B.A. (Age 49)Group Chief Commercial Officer Comp: $425.87kMr. Darren Patti (Age 52)Group Chief Operating Officer Dr. Michael Wheatcroft B.Sc.BSc(Hons), Ph.D., Ph.D., (Cantab), Chief ScientistMr. Craig UlrickChief Information OfficerMs. Kyahn Williamson B.A.Senior Vice President of Corporate Communications & Investor RelationsMs. Melanie Farris (AGIAACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Senior VP of Global Governance, Risk & ComplianceMs. Lena Moran-Adams L.L.B.Group General CounselThomas FrommVice President of SalesMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors TLPPF Stock Analysis - Frequently Asked Questions Should I buy or sell Telix Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Telix Pharmaceuticals in the last twelve months. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" TLPPF shares. View TLPPF analyst ratings or view top-rated stocks. How have TLPPF shares performed in 2024? Telix Pharmaceuticals' stock was trading at $6.8750 on January 1st, 2024. Since then, TLPPF stock has increased by 83.8% and is now trading at $12.6340. View the best growth stocks for 2024 here. Are investors shorting Telix Pharmaceuticals? Telix Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,235,900 shares, an increase of 59.8% from the May 31st total of 1,399,600 shares. Based on an average daily volume of 23,300 shares, the short-interest ratio is presently 96.0 days. View Telix Pharmaceuticals' Short Interest. How do I buy shares of Telix Pharmaceuticals? Shares of TLPPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:TLPPF) was last updated on 7/3/2024 by MarketBeat.com Staff From Our PartnersOperation Replace Biden is a GoLast night’s debate proved me right: Joe Biden will be replaced. I’ve been making this warning for months… ...The Freeport Society | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe End of Privacy for Americans… Get Out of Cash Now!Unlock the Secret to Outsmarting Inflation with "The Trump Loophole" That investment? Gold.Golden Crest | SponsoredElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine...InvestorPlace | SponsoredSilver Expected for Extreme Price ActionOur newest Silver Investing Guide reveals how savvy investors are capitalizing on silver's continued rise – PL...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
